Theophylline for erythrocytosis after renal transplantation

Richard S. Beach, Deborah Donlon, Danilo Escoto, Jeane McCarthy, Anthony Napolitano, Roberto Sosa, George L. Bakris, Nancy A. Lass

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: As was noted in the article on the use of theophylline to treat erythrocytosis in renal-transplant recipients (July 12 issue),1 theophylline suppresses the production of erythropoietin in both normal subjects and renal-transplant recipients with increased red-cell mass due to elevated levels of erythropoietin production and release. The use of theophylline allowed patients with such erythrocytosis to avoid weekly phlebotomy. A large percentage of preterm infants have apnea, and the current treatment of choice in most clinical settings is theophylline.2 These same infants often have clinically important anemia of prematurity, requiring frequent transfusions.3 It has been suggested that.

Original languageEnglish (US)
Pages (from-to)1635
Number of pages1
JournalNew England Journal of Medicine
Volume323
Issue number23
DOIs
StatePublished - Dec 6 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Theophylline for erythrocytosis after renal transplantation'. Together they form a unique fingerprint.

Cite this